JP6669868B2 - フタラジン誘導体、その製造方法、医薬組成物および使用 - Google Patents

フタラジン誘導体、その製造方法、医薬組成物および使用 Download PDF

Info

Publication number
JP6669868B2
JP6669868B2 JP2018530763A JP2018530763A JP6669868B2 JP 6669868 B2 JP6669868 B2 JP 6669868B2 JP 2018530763 A JP2018530763 A JP 2018530763A JP 2018530763 A JP2018530763 A JP 2018530763A JP 6669868 B2 JP6669868 B2 JP 6669868B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
alkoxy
independently
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018530763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537480A5 (enExample
JP2018537480A (ja
Inventor
シュアイ リー，
シュアイ リー，
ヨン スン，
ヨン スン，
Original Assignee
シャンハイ エスアイエムアール バイオテク カンパニー リミテッド
シャンハイ エスアイエムアール バイオテク カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ エスアイエムアール バイオテク カンパニー リミテッド, シャンハイ エスアイエムアール バイオテク カンパニー リミテッド filed Critical シャンハイ エスアイエムアール バイオテク カンパニー リミテッド
Publication of JP2018537480A publication Critical patent/JP2018537480A/ja
Publication of JP2018537480A5 publication Critical patent/JP2018537480A5/ja
Application granted granted Critical
Publication of JP6669868B2 publication Critical patent/JP6669868B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018530763A 2015-12-08 2016-12-08 フタラジン誘導体、その製造方法、医薬組成物および使用 Active JP6669868B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510900083.4 2015-12-08
CN201510900083.4A CN106854207B (zh) 2015-12-08 2015-12-08 呔嗪类衍生物、其制备方法、药物组合物和用途
PCT/CN2016/108975 WO2017097217A1 (zh) 2015-12-08 2016-12-08 呔嗪类衍生物、其制备方法、药物组合物和用途

Publications (3)

Publication Number Publication Date
JP2018537480A JP2018537480A (ja) 2018-12-20
JP2018537480A5 JP2018537480A5 (enExample) 2019-02-28
JP6669868B2 true JP6669868B2 (ja) 2020-03-18

Family

ID=59013670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018530763A Active JP6669868B2 (ja) 2015-12-08 2016-12-08 フタラジン誘導体、その製造方法、医薬組成物および使用

Country Status (5)

Country Link
US (1) US11220503B2 (enExample)
EP (1) EP3388433B1 (enExample)
JP (1) JP6669868B2 (enExample)
CN (1) CN106854207B (enExample)
WO (1) WO2017097217A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110256440B (zh) * 2018-03-12 2023-05-23 上海赛默罗生物科技有限公司 酞嗪异噁唑烷氧基衍生物、其制备方法、药物组合物和用途
CN112979655A (zh) 2019-12-16 2021-06-18 上海赛默罗生物科技有限公司 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
TW202237578A (zh) * 2020-12-01 2022-10-01 英商卡爾維斯塔製藥有限公司 酶抑制劑
CN112441901B (zh) * 2020-12-15 2023-08-29 山东泰和科技股份有限公司 一种乙酸酐的合成方法
CN116008443B (zh) * 2023-03-28 2023-06-30 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂类药物中有关物质的检测方法
TW202446381A (zh) * 2023-05-26 2024-12-01 大陸商武漢人福創新藥物研發中心有限公司 作為α5-GABAA受體調節劑的雜環化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112504D0 (en) 1991-06-11 1991-07-31 Merck Sharp & Dohme Cell line
US5652100A (en) 1992-12-10 1997-07-29 Merck Sharpe & Dohme Ltd. Stably transfected rodent fibroblast cell lines expressing human GABA-A -receptors
CA2288789C (en) 1997-05-08 2009-07-21 Merck Sharp & Dohme Limited Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands
GB9715977D0 (en) 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
US6297235B1 (en) 1997-08-28 2001-10-02 Merck Sharp & Dohme Ltd. Triazolopyridazine derivatives for treating anxiety and enhancing cognition
ES2195943T3 (es) 1999-11-12 2003-12-16 Neurogen Corp Compuestos heteroaromaticos biciclicos y triciclicos.
GB0028583D0 (en) 2000-11-23 2001-01-10 Merck Sharp & Dohme Therapeutic compounds
US20050043982A1 (en) * 2003-08-22 2005-02-24 Nguyen Vinh Dinh Contextual workflow modeling
CN1871008A (zh) * 2003-10-21 2006-11-29 默克公司 用于治疗神经病变性疼痛的三唑并－哒嗪化合物和它们的衍生物
US10206921B2 (en) 2009-06-03 2019-02-19 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (CNS) injury
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain

Also Published As

Publication number Publication date
WO2017097217A1 (zh) 2017-06-15
EP3388433B1 (en) 2023-08-30
JP2018537480A (ja) 2018-12-20
CN106854207B (zh) 2019-10-29
US20200165253A1 (en) 2020-05-28
EP3388433A1 (en) 2018-10-17
CN106854207A (zh) 2017-06-16
US11220503B2 (en) 2022-01-11
EP3388433A4 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
JP6669868B2 (ja) フタラジン誘導体、その製造方法、医薬組成物および使用
CN110256440B (zh) 酞嗪异噁唑烷氧基衍生物、其制备方法、药物组合物和用途
CA3165238A1 (en) Kras mutant protein inhibitors
JP6782255B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
CA2957046C (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
AU2018208848A1 (en) Heterocyclic spiro compounds as MAGL inhibitors
KR20150135794A (ko) 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도
TWI872177B (zh) 對核受體具有活性之化合物
JP2021526123A (ja) オートタキシン阻害剤とその使用
CA2890685A1 (en) Substituted 1,6-naphthyridines
CN107344936B (zh) 三唑哒嗪类衍生物、其制备方法、药物组合物和用途
KR20210072787A (ko) 저분자 메닌 억제제
CN107344938B (zh) 吡唑-三嗪类衍生物、其制备方法、药物组合物和用途
AU2014365915C1 (en) Tetrahydro-tetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors
KR102882869B1 (ko) 이미다조피리다진계 유도체, 이의 제조 방법, 약학 조성물 및 용도
CA3199269A1 (en) Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CN107344939A (zh) 咪唑[2,1-a]酞嗪类衍生物、其制备方法、药物组合物和用途
WO2023152182A1 (en) Novel compounds modulating mir-155
CN107344937A (zh) 三唑并[1,5-a]喹唑啉类衍生物、其制备方法、药物组合物和用途
HK40097285A (zh) Myc家族原癌基因蛋白的调节剂
HK40077526B (zh) 对核受体具有活性的化合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200227

R150 Certificate of patent or registration of utility model

Ref document number: 6669868

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250